TY  - JOUR
AU  - Díez-Campelo, María
AU  - Lorenzo, Jose I
AU  - Itzykson, Raphael
AU  - Rojas, Silvia M
AU  - Berthon, Céline
AU  - Luño, Elisa
AU  - Beyne-Rauzy, Odile
AU  - Perez-Oteyza, Jaime
AU  - Vey, Norbert
AU  - Bargay, Joan
AU  - Park, Sophie
AU  - Cedena, Teresa
AU  - Bordessoule, Dominique
AU  - Muñoz, Juan A
AU  - Gyan, Emmanuel
AU  - Such, Esperanza
AU  - Visanica, Sorin
AU  - López-Cadenas, Félix
AU  - de Botton, Stéphane
AU  - Hernández-Rivas, Jesús M
AU  - Ame, Shanti
AU  - Stamatoullas, Aspasia
AU  - Delaunay, Jacques
AU  - Salanoubat, Celia
AU  - Isnard, Françoise
AU  - Guieze, Romain
AU  - Pérez Guallar, Joan
AU  - Badiella, Llorenc
AU  - Sanz, Guillermo
AU  - Cañizo, Consuelo
AU  - Fenaux, Pierre
PY  - 2018
DO  - 10.1111/bjh.15190
UR  - http://hdl.handle.net/10668/12302
T2  - British journal of haematology
AB  - Treatment with azacitidine (AZA) has been suggested to be of benefit for higher-risk myelodysplastic syndrome (HR-MDS) patients with chromosome 7 abnormalities (Abn 7). This retrospective study of 235 HR-MDS patients with Abn 7 treated with AZA...
LA  - en
KW  - azacitidine
KW  - chromosome 7 abnormalities
KW  - high risk MDS
KW  - time-dependent analysis
KW  - Aged
KW  - Azacitidine
KW  - Chromosome Aberrations
KW  - Chromosomes, Human, Pair 7
KW  - Disease-Free Survival
KW  - Female
KW  - Humans
KW  - Male
KW  - Middle Aged
KW  - Myelodysplastic Syndromes
KW  - Registries
KW  - Retrospective Studies
KW  - Risk Factors
KW  - Survival Rate
TI  - Azacitidine improves outcome in higher-risk MDS patients with chromosome 7 abnormalities: a retrospective comparison of GESMD and GFM registries.
TY  - research article
VL  - 181
ER  -